Yüklüyor......
Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3796852/ https://ncbi.nlm.nih.gov/pubmed/24133375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IBPC.S13783 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|